Accelerated regulatory approval in 2022 and beyond – managing uncertainty with the impact of Brexit and COVID
Now available to watch on-demand
After COVID-19 and Brexit have brought about significant global impacts, focusing on accelerating regulatory approval in 2022 and beyond deserves even greater attention than before.
To attack this question, this panel discussion will investigate how regulators have typically handled areas of unmet need, navigating reimbursement pathways in the UK compared to abroad, what the future picture of accelerated regulatory approval may look like and how NICE’s new guidance will affect this.
Catch up on this insightful discussion below.
What will you learn?
- How have regulators typically handled areas of unmet need
- Navigating UK vs other reimbursement pathways
- The future picture of accelerated regulatory approval
- How the new NICE guidance on RWE will affect the field
Who may this interest?
- Pharma, biotech and medical device companies
- Regulators
- HTAs
- Payers
- Academics and researchers in RWE, big data and HEOR
- Patient advocacy groups
- Market access specialists
- Consultants
- Leaders in business insights
Speakers
Leslie Galloway
Chairman
EMIG (London, UK)
Leslie was elected as Chairman of EMIG in 2005 and has been instrumental in its metamorphosis from its origins as a business and networking group to the influential trade association it is today.
In July 2014, Leslie was elected as Vice President of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE, Brussels, Belgium) and appointed to the Board of the European Union Medical Cannabis Association (Brussels, Belgium) in 2019. Leslie was also Vice Chairman of the NICE Project Development Group for Local Formularies Good Practice Guidance (London, UK), a member of the NICE Medicines Optimization Guidance Development Group (London, UK) and is currently an expert adviser to the NICE Centre for Clinical Practice (London, UK).
In April 2020, Leslie became co-Founder and Chairman of TetrisPharma Ltd (Marlow, UK).
Melvin ‘Skip’ Olson
Global Head of Integrated Evidence Strategy and Innovation
Novartis (Basel, Switzerland)
Skip Olson is currently the Global Head of Integrated Evidence Strategy and Innovation at Novartis. As such, he is responsible for promoting the very best in research methodology and applications of real-world evidence (RWE), and other evidence, across all therapeutic areas and around the globe to drive better decision-making.
He comes from a background in health economics and outcomes research, where he has led the utilization of RWE to transform the generation of patient insights and value for money assessments. He earned a ScD in biostatistics from Harvard University (MA, US) and has worked in the pharmaceutical industry for nearly 30 years.
Martin Strandberg-Larsen
Senior Director of Market Access
Veracyte (CA, USA)
Martin Strandberg-Larsen is a life science leader with a passion for market access and health economics to bring new innovations to patients. He has worked in the pharmaceutical and medtech industries since 2008. He has experience as a global and regional lead and currently is focused on precision medicine in oncology and pulmonology, as Senior Director of Market Access at Veracyte (CA, USA) and previously AstraZeneca (Cambridge, UK). He holds a doctoral degree in health sciences from the University of Copenhagen (Denmark).